HIV Preexposure Prophylaxis Care Continuum Among Individuals Receiving Medication for Opioid Use Disorder, South Carolina, 2020-2021
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
We implemented the HIV preexposure prophylaxis (PrEP) care continuum among individuals receiving medication for opioid use disorder (MOUD). We screened HIV-negative MOUD participants for PrEP eligibility by assessing injection drug use risk factors and sexual behaviors. Implementation of the PrEP care continuum was challenging; less than a third of MOUD participants were aware of PrEP, and very few initiated PrEP. Findings should promote the development of effective interventions to increase engagement in PrEP during MOUD treatment. (. 2022;112(1):34-37. https://doi.org/10.2105/AJPH.2021.306566).
References
1.
Smith D, Pals S, Herbst J, Shinde S, Carey J
. Development of a clinical screening index predictive of incident HIV infection among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2012; 60(4):421-7.
DOI: 10.1097/QAI.0b013e318256b2f6.
View
2.
Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock P, Leethochawalit M
. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013; 381(9883):2083-90.
DOI: 10.1016/S0140-6736(13)61127-7.
View
3.
Smith D, Pan Y, Rose C, Pals S, Mehta S, Kirk G
. A Brief Screening Tool to Assess the Risk of Contracting HIV Infection Among Active Injection Drug Users. J Addict Med. 2015; 9(3):226-32.
PMC: 4449303.
DOI: 10.1097/ADM.0000000000000123.
View
4.
Nunn A, Brinkley-Rubinstein L, Oldenburg C, Mayer K, Mimiaga M, Patel R
. Defining the HIV pre-exposure prophylaxis care continuum. AIDS. 2017; 31(5):731-734.
PMC: 5333727.
DOI: 10.1097/QAD.0000000000001385.
View